Claims:

Claim 1. A complex for use with an enhanced delivery vehicle, which comprises:

CBD derived from Hemp Oil or otherwise, and synthetics identical with the same;

and at least one hydrogel that comprises one or more of poly(ethylene oxide) (PEO), poly(propylene oxide) (PPO), poly(lactide-co-glycolic acid) (PLGA), poly(N-isopropylacrylamide) (PNIPAM), poly(propylene fumarate) (PPF), poly(caprolactone) (PCL), poly(urethane) (PU), poly(organophosphazene) (POP), the block polymer PEO-PPO-PEO, and ethylene vinylacetate,

an adhesive comprising a cycloaliphatic hydrocarbon resin,

an acrylic adhesive with non-functionality,

and at least one additional moiety functioning as an active from the group consisting essentially of sildenafil; melatonin; vitamins B_1, D_3, B_{12} and capsaicin/capsicum and related salts; dihydromyricetin; and LIDOCAINE®,.

Claim 2. The Complex of claim 1, which further comprises at least one of:

(a) An acrylic adhesive with non-functionality and an adhesive with only OH-functionality, further comprising one of more of enhancers selected from azone, oleic acid, and dimethylsulfoxide (DMSO);

(b) A polyisobutylene (PIB adhesive) with tackifiers that improve adhesion to skin using acrylic pressure sensitive adhesive mixed in at 1-50%, optionally with a cycloaliphatic hydrocarbon resin;

(c) PIB adhesive with enhancers: at 3% of Azon or oleic acid double the transdermal delivery from PIB. The disclosure provides a graph showing transdermal flux;

(d) Hemp oil with CBD of concentration 80-95% containing at least one terpene;

(e) A semisolid hydrogel that is saturated with cannabidiol (CBD) and tetrahydrocannabinol (THC);

(f) A semisolid hydrogel comprising an oil that consists essentially of CBD and THC (80-95%, wt/vol), in combination with ethanol/water (80/20, vol/vol), optionally with one or more enhancers selected from azone, oleic acid, and limonene;

(g) A semisolid hydrogel saturated with CBD and THC oils (80-95%, wt/vol), wherein the oil is mixed with EtOH /water (80/20, vol/vol), optionally with one or more enhancers selected from azone, oleic acid, and limonene; or

(h) A THC oil of THC (80-95%) mixed with 1-20% EtOH/water or with 1-10% EtOH/water (80/20, vol/vol) wherein including greater than 10% of ethanol is capable of lowering flux of THC delivery as determinable with a reservoir patch.

Claim 3. A sublingual pill comprising a complex of Claim 2,

wherein additionally said pill comprises a hardness value, and a disintegration value allowing passage of the active ingredient into a subject.

Claim 4. A transdermal patch comprising a complex of Claim 2.

Claim 5. The transdermal patch, of Claim 4, further comprising a plurality of microneedles.

Claim 6. A method for applying the sublingual pill of claim 3 to the buccal mucosa of a subject, and allowing a cannabinoid to transit from the patch into an oral mucosa of the subject.

Claim 7. A method for applying the transdermal patch of Claim 5 to skin of a subject, and allowing a cannabinoid to transit from the buccal patch into the skin of the subject.

Claim 8. A method for manufacturing the device with a complex of Claim 4, comprising; the steps of;

combining the same with THC, a film, an adhesive, and a backing, to generate an uncut patch, further comprising the uncut patch to produce a cut patch that is capable of applying to skin.

Claim 9. The method of claim 8, further comprising a database of information governed by artificial intelligence (AI) made-up of all information and data generated by the method.

Claim 10. Apparatus, embodying machines to manufacture patches and pills according to the Method of claim 8 with AI.

Claim 11. The complex of claim 1, effectively compounded with other ingredients to be safely edible.

Claim 12. The complex of claim 1, effectively compounded with other ingredients to be safely potable.

Claim 13. The complex of claim 1, compounded with effective and safe ingredients to be injected or inhaled.

Claim 14. The complex of Claim 1, further comprising one or more of vitamin C, salicylic acid, and terpenes.

Claim 15. The complex of Claim 1 that does not include any cyclodextrin.

Claim 16. The complex of Claim 1, wherein the at least one hydrogel is cross-linked with a cyclodextrin, and wherein the cyclodextrin comprises a beta-cyclodextrin such as hydroxypropyl-beta-cyclodextrin, sulfobutylether-beta-cyclodextrin, maltoxyl-beta-cyclodextrin, methylated cyclodextrin, alpha-cyclodextrin (6 glucopyranose units), beta-cyclodextrin (7 glucopyranose units), and gamma-cyclodextrin (8 glucopyranose units).

Claim 17. The complex of Claim 1, wherein the at least one hydrogel is cross-linked with a cyclodextrin, and wherein the cyclodextrin consists of a beta-cyclodextrin such as hydroxypropyl-beta-cyclodextrin, sulfobutylether-beta-cyclodextrin, maltoxyl-beta-

cyclodextrin, methylated cyclodextrin, alpha-cyclodextrin (6 glucopyranose units), beta-cyclodextrin (7 glucopyranose units), and gamma-cyclodextrin (8 glucopyranose units).